| |
|
Register Now!
Expert Practice SM
in Lung Cancer
Madrid, Spain
April 5, 2008
|
Registration |
|
Registration is closed.
|
|
FACULTY
Giorgio Scagliotti, MD (Italy)
Pieter Postmus, MD (Netherlands)
Ugo Pastorino, MD (Italy)
Suresh Senan, MD (Netherlands)
Nick Thatcher, MD (UK)
Luis Paz-Ares, MD (Spain)
Peter Harper, MD (UK)
|
|
On behalf of the co-chairs, Dr. Giorgio Scagliotti,
and Dr. Pieter Postmus, we are pleased to invite
you to the Expert Practice in Lung cancer meeting
in Madrid, Spain, 5 April 2008.
During this case-based meeting, leaders in the
field discuss clinical issues encountered daily with
participants in an interactive format.
Tentative Agenda
Friday, 4 April 2008
Arrival in Madrid - Reception and Dinner: 20.00 - 22.00
Saturday, 5 April 2008
|
| 08:00–08:15 |
Welcome and
Introduction |
G. Scagliotti,
MD
P. Postmus, MD |
| 08:15-08:45 |
Case #1 -
NSCLC Stage IV: Progression After
Response To First Line Therapy |
N. Thatcher, MD |
| 08:45–09:15 |
Case #2 -
Extensive Stage SCLC |
L. Paz-Ares, MD |
| 09:15–09:30 |
Ask The
Experts & Panel Discussion |
|
| 09:-30–10:00 |
Coffee
Break |
|
| 10:00–10:30 |
Case #3 -
NSCLC Stage IIIB, Multidisciplinary
Management |
S. Senan, MD |
| 10:30–11:00 |
Case #4 -
NSCLC Stage IV: Optimizing Clinical
Outcomes |
P. Harper, MD |
| 11:00–11:15 |
Ask The
Experts & Panel Discussion |
|
|
11:15–11:45 |
Debate: Molecular Targeted Therapies
Will Replace Cytotoxic Chemotherapy In
The Near Future |
Pro: N.
Thatcher, MD |
| Contra: G.
Scagliotti, MD |
| 11:45–12:45 |
Lunch |
|
| 12:45–13:15 |
Lecture:
How to be an Effective Member of a
Multidisciplinary Team |
S. Senan, MD |
| 13:15–13:45 |
Case #5 -
NSCLC Stage IIIA, Optimal Management |
U. Pastorino, MD |
| 13:45–14:15 |
Case #6 -
NSCLC With a Single Metastasis |
P. Postmus, MD |
| 14:15–14:30 |
Ask The
Experts & Panel Discussion |
|
| 14:30–15:00 |
Case #7 -
NSCLC Stage I With Severe COPD |
P. Postmus, MD |
| 15:00–15:30 |
Case #8 -
Elderly NSCLC, Male, Non-smoker |
L. Paz-Ares, MD |
| 15:30–15:45 |
Ask The
Experts & Panel Discussion |
|
| 15:45 |
Concluding
Remarks |
G. Scagliotti, MD
P. Postmus, MD |
| |
|
|
| |
|
|
Click
here for more information
|
|
|
|
